O le a le uiga o le “manino”?
E le tauaveina e le manu le suiga. O le a le tupu ai le ma'i ma o le a lē tuʻuina atu.
Maile Mata'i Mata'i Tuila (MH)
Discover the importance of DNA testing for Canine Malignant Hyperthermia (MH) in dogs. This genetic disorder can lead to severe reactions during anesthesia, placing your furry friend at risk. By identifying the MH gene mutation through a simple DNA test, pet owners can make informed decisions about their dog's health and safety. Early detection allows for proactive management, ensuring a safer experience during veterinary procedures. Investing in a DNA test for Canine Malignant Hyperthermia can ultimately save lives and enhance your dog's well-being. Consult your veterinarian today to learn more about this vital genetic screening. Protect your pup with knowledge and peace of mind!
Faapuupuuga: MH
Su'ega su'esu'e: RYR1 c.1643T>C
Tofi: Autosomal Pulea
Acronym
MH
Mata'ituina taimi
Fa'alema'i ogaoga
Fa'avasegaga fa'apitoa
Fa'ama'i Metabolic
Iloiloga suiga
RYR1 c.1643T>C
p.(V548A)
p.(V548A)
Faiga o tofi
Autosomal Pulea
Aotelega o su'ega:
Canine Malignant Hyperthermia (MH) is a rare genetic disorder triggered by certain anesthetic agents in dogs. It leads to a severe and uncontrolled increase in body temperature, muscle rigidity, and metabolic disturbances. The condition is often linked to mutations in the ryanodine receptor gene. Prompt recognition and immediate treatment are crucial to prevent serious complications or death. Preventive measures include genetic testing and avoiding specific anesthetics in at-risk breeds.
E maua mai le pusa: Basic
O lenei su'ega DNA e aofia ai e amata mai i le matou pusa Basic — ma o se vaega foi o pusa Basic, Standard, Advanced, Complete.
Va'ai DNA Su'ega Packs →Filifili le pusa e sili ona fetaui ma lau faʻatupuina poʻo le soifua maloloina o au manu.
Introduction to Canine Malignant Hyperthermia (MH)
Canine Malignant Hyperthermia (MH) is a rare but serious genetic disorder that affects certain dog breeds. It is characterized by an abnormal and severe response to specific stressors, such as anesthesia or extreme heat, leading to a rapid increase in body temperature and metabolic crisis. If not recognized and treated promptly, MH can be fatal for the affected dog.
Understanding the Condition
Malignant Hyperthermia in dogs is caused by a hereditary defect in the regulation of calcium within muscle cells. This defect leads to uncontrolled muscle contractions and a significant increase in metabolic activity, resulting in a rapid rise in core body temperature. Symptoms often include muscle rigidity, rapid breathing, increased heart rate, and a sudden onset of hyperthermia. The condition is often triggered by certain anesthetic agents or stress, making perioperative management critical.
Genetic Basis of Canine MH
The disorder is inherited in a manner similar to that observed in humans, with specific genetic mutations affecting calcium regulation pathways. Dogs carrying these mutations are predisposed to developing MH when exposed to triggering factors. Identifying affected dogs through DNA testing allows breeders and veterinarians to make informed decisions to prevent the spread of the disorder and to implement appropriate management strategies for affected animals.
The Role of DNA Testing
DNA testing for canine MH involves analyzing specific genetic markers associated with the disorder. This test provides valuable information about an individual dog's genetic status, helping to identify carriers or affected animals. Early detection through DNA testing can assist in making preventative choices, such as avoiding certain medications or stressful situations that could trigger a crisis, thereby safeguarding the health and well-being of the dog.
Importance of Diagnosis and Management
Accurate diagnosis of MH through DNA testing is essential for effective management. Dogs identified as at risk can be provided with tailored anesthetic protocols, monitored closely during procedures, and kept in a stress-free environment. Additionally, knowing a dog’s genetic status helps inform breeding decisions to reduce the prevalence of the disorder within a breed population.
Fa'ailoga ua iloa mo le su'ega: Mata'i Mata'i Tuila (MH)
- Bearded Collie
- Border Collie
- Doberman Pinscher
- Farm Collie
- German Shepherd Dog
- Labrador Retriever
- Old Farm Collie
- Rough Collie
- Scottish Collie
- Scottish Rough Collie
- Scottish Smooth Collie
- Smooth Collie
🧬 Interpretation of genotypes MH
Genotype
Tulaga
🟡 N/N
E le fa'asalalau - Leai se lamatiaga
🟡 N/MH
Carrier - At Risk
❌ MH/MH
A'afia - I Tulaga lamatia
FAQ: malamalama i le fa'amatalaga
E mata'utia ea se “Vaveina”?
Leai. E masani ona soifua maloloina le manu ae e mafai ona tuʻuina atu le suiga i lona fanau.
Ae faapefea pe a “Aafia” se manu?
E lua kopi suia. Fa'ailoga fa'afoma'i e fa'amoemoe e fa'atatau i le faama'i. E le tatau ona fafaga.
Aisea e iai le eseesega i le va o tane / fafine?
O nisi faʻamaʻi e fesoʻotaʻi feusuaʻiga, o lea e eseese ai o latou faʻaaliga e faʻatatau i le itupa a manu.
Va'ai le Fanau
N/N (le-faasalalau)
N/MH (Va'ava'a)
MH/MH (A’afia)
Su'ega DNA FAQ
O le a le mea e iloa e lenei su'ega DNA?
This DNA test detects the mutation associated with Canine Malignant Hyperthermia (MH) in order to identify clear, carrier, or at-risk animals.
Aisea e su'e ai se manu faifa'ato'aga?
O le su'ega DNA e fesoasoani i le au faifa'ato'aga e fuafua ni faigauo saogalemu ma fa'aitiitia ai le lamatiaga o le tu'uina atu o le suiga i fanau.
O le a le tulaga tofi o lenei suega?
Ole fa'asologa ole tofi na lipotia mo lenei su'ega ole Autosomal Dominant.
O le fea suiga o lo'o su'esu'eina i lenei su'ega?
This test analyses the mutation RYR1 c.1643T>C.
E a'afia se manu fe'avea'i?
E le faapea. O le fa'auigaina e fa'alagolago i le fa'asologa o tofi ma le fa'atupuina o le genotype.
Fa'asinomaga
Roberts M C, Mickelson J R, Patterson E E, Nelson T E, Armstrong P J, Brunson D B, Hogan K. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology. 2001 Sep;95(3):716-25. doi: 10.1097/00000542-200109000-00026.